CNS Tumor with BCOR/BCORL1 Fusion: A Rare Tumor Entity
International Journal of Molecular Sciences · 14.07.2025 · 26 (14) · 6729
DOI: 10.3390/ijms26146729 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.07.2025. Verfasst von Jerry Lou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of California Irvine, Irvine, CA 92697, USA. Hauptthemen laut MEDLINE: Repressor Proteins, Proto-Oncogene Proteins, Central Nervous System Neoplasms, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Central nervous system (CNS) tumor with BCL6 corepressor gene BCOR/BCORL1 fusion is an extremely rare tumor entity, with fewer than 40 cases reported. These tumors are distinct from the WHO 2021-defined CNS tumor with BCOR internal tandem duplication. Even rarer are CNS tumors that match to the methylation class of CNS tumors with BCOR/BCORL1 fusion, but lack fusions and instead harbor truncating small nucleotide variants in BCOR. To our knowledge, only two other cases of this scenario have been previously reported. Due to their scarcity and morphological features that mimic oligodendrogliomas and ependymomas, the diagnosis of CNS tumor with BCOR/BCORL1 fusion can be challenging, and misdiagnoses are not uncommon. Histologic findings of Olig2 positivity with focal to absent GFAP warrant further evaluation for this tumor entity. Moreover, no standard of care therapy exists for these tumors, making treatment selection difficult. We present a case of a 37-year-old woman with a midline CNS tumor with BCOR/BCORL1 fusion, harboring a pathogenic BCOR c.626del (p.S209Cfs*7) (Exon 4) variant, who was successfully treated with definitive radiation therapy and adjuvant temozolomide. Notably, EMA showed focal strong dot-like perinuclear immunoreactivity, which has not been previously reported in these tumors. This case adds to the limited but growing body of evidence supporting the use of radiation and temozolomide in treating tumors matching the methylation class of CNS tumors with BCOR/BCORL1 fusion without a detectable fusion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of California Irvine, Irvine, CA 92697, USA.
- Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92697, USA.
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- Department of Radiology, University of California Irvine, Irvine, CA 92697, USA.
- Department of Radiation Oncology, University of California Irvine, Irvine, CA 92697, USA.
- Department of Neurosurgery, University of California Irvine, Irvine, CA 92697, USA.
ORCID-Profile: Jerry Lou, Eleanor Chu, Anatevka Ribeiro, Carlen A Yuen
Förderung
- NCI NIH HHS
Zitieren
APA
Lou, J., Yong, W., Aldape, K., Chu, E., Hui, C., Hsu, F. P. K., Zheng, M., Ribeiro, A., Fote, G., Na, D., & Yuen, C. A. (2025). CNS Tumor with BCOR/BCORL1 Fusion: A Rare Tumor Entity. International Journal of Molecular Sciences, 26(14), 6729. https://doi.org/10.3390/ijms26146729
Vancouver
Lou J, Yong W, Aldape K, Chu E, Hui C, Hsu FPK, et al. CNS Tumor with BCOR/BCORL1 Fusion: A Rare Tumor Entity. International Journal of Molecular Sciences. 2025;26(14):6729. doi:10.3390/ijms26146729
BibTeX
@article{Lou2025,
author = {Lou, Jerry and Yong, William and Aldape, Kenneth and Chu, Eleanor and Hui, Caressa and Hsu, Frank P K and Zheng, Michelle and Ribeiro, Anatevka and Fote, Gianna and Na, Daniel and Yuen, Carlen A},
title = {CNS Tumor with BCOR/BCORL1 Fusion: A Rare Tumor Entity},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {14},
pages = {6729},
doi = {10.3390/ijms26146729}
}
EUVIMED